{Reference Type}: Journal Article
{Title}: Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis.
{Author}: Murphy MJ;Cohen JM;Vesely MD;Damsky W;
{Journal}: J Am Acad Dermatol
{Volume}: 0
{Issue}: 0
{Year}: Dec 2020 8
{Factor}: 15.487
{DOI}: 10.1016/j.jaad.2020.12.010
{Abstract}: <B>BACKGROUND: </B>Antibody-based therapies that inhibit proinflammatory cytokine signaling are commonly used in dermatology. Paradoxically, these medications may induce or exacerbate inflammatory disorders.<BR><B>OBJECTIVE: </B>To summarize the spectrum of manifestations, incidence, timing, potential mechanisms of, and general management approaches to paradoxical cutaneous reactions induced by cytokine-targeted antibodies in dermatology.<BR><B>METHODS: </B>We performed a systematic review and analysis of published cases of cutaneous paradoxical reactions (PRs) reported in association with tumor necrosis factor α, interleukin (IL) 12/23 (p40), IL-17A/17R, IL-23 (p19), and IL-4Rα inhibitors.<BR><B>RESULTS: </B>We identified 313 articles reporting 2049 cases of PRs. Tumor necrosis factor α inhibitors resulted in 91.2% (1869/2049) of all cases, followed by IL-17/17R (3.5%), IL-4Rα (2.7%), IL-12/23 (2.4%), and IL-23 (0.01%) inhibitors. Psoriasiform and eczematous eruptions were the most commonly reported, but a wide spectrum of patterns were described. Phenotypically overlapping reaction patterns were common. Time to onset typically ranged from weeks to months but could occur more than a year later. Improvement or resolution upon discontinuation of the inciting drug was common.<BR><B>CONCLUSIONS: </B>This was a retrospective analysis.<BR><B>CONCLUSIONS: </B>Familiarity with the clinical features of PRs from cytokine-blocking antibodies may facilitate efficient recognition and management.